EP3515444A4 - Composition for treating ocular diseases and methods of usage and making - Google Patents

Composition for treating ocular diseases and methods of usage and making Download PDF

Info

Publication number
EP3515444A4
EP3515444A4 EP17852151.4A EP17852151A EP3515444A4 EP 3515444 A4 EP3515444 A4 EP 3515444A4 EP 17852151 A EP17852151 A EP 17852151A EP 3515444 A4 EP3515444 A4 EP 3515444A4
Authority
EP
European Patent Office
Prior art keywords
usage
composition
making
methods
ocular diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17852151.4A
Other languages
German (de)
French (fr)
Other versions
EP3515444A1 (en
Inventor
Shuhua Guo
Jiewen ZHONG
Xinting YUAN
Zongren YAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reyoung (suzhou) Biology Science & Technology Co Ltd
Original Assignee
Reyoung (suzhou) Biology Science & Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reyoung (suzhou) Biology Science & Technology Co Ltd filed Critical Reyoung (suzhou) Biology Science & Technology Co Ltd
Publication of EP3515444A1 publication Critical patent/EP3515444A1/en
Publication of EP3515444A4 publication Critical patent/EP3515444A4/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
EP17852151.4A 2016-09-26 2017-05-19 Composition for treating ocular diseases and methods of usage and making Pending EP3515444A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610849023 2016-09-26
PCT/CN2017/084994 WO2018054077A1 (en) 2016-09-26 2017-05-19 Composition for treating ocular diseases and methods of usage and making

Publications (2)

Publication Number Publication Date
EP3515444A1 EP3515444A1 (en) 2019-07-31
EP3515444A4 true EP3515444A4 (en) 2020-06-03

Family

ID=61689743

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17852151.4A Pending EP3515444A4 (en) 2016-09-26 2017-05-19 Composition for treating ocular diseases and methods of usage and making

Country Status (5)

Country Link
US (1) US10772885B2 (en)
EP (1) EP3515444A4 (en)
JP (1) JP7018939B2 (en)
CN (1) CN107865821B (en)
WO (1) WO2018054077A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11278546B2 (en) * 2016-07-22 2022-03-22 Aiviva Biopharma, Inc. Multikinase inhibitors and uses in ocular fibrosis
WO2019197961A1 (en) * 2018-04-09 2019-10-17 Intas Pharmaceuticals Ltd. Pharmaceutical composition of nintedanib esylate
CA3110287A1 (en) 2018-08-28 2020-03-05 Cloudbreak Therapeutics, Llc Emulsion formulations of multikinase inhibitors
SG11202106144VA (en) * 2018-12-11 2021-07-29 Disruption Labs Inc Compositions for the delivery of therapeutic agents and methods of use and making thereof
CN109908328A (en) * 2019-03-25 2019-06-21 华南理工大学 Nanometer percutaneous technique is used to improve the eye sticker and preparation method thereof of eyes xerophthalmia
CN115645420A (en) * 2021-07-07 2023-01-31 苏州普乐康医药科技有限公司 Application of mannose and medicinal derivatives thereof in preparation of medicines for preventing and/or treating age-related macular degeneration
WO2024037982A1 (en) 2022-08-16 2024-02-22 Boehringer Ingelheim International Gmbh Pharmaceutical formulations of nintedanib for intraocular use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4228195B2 (en) 2002-02-22 2009-02-25 参天製薬株式会社 Subconjunctival drug delivery system
CN1376463A (en) * 2002-03-29 2002-10-30 沈阳药科大学 Inclusion compound of disulfiram as eye drops and its preparing process
DE10233500A1 (en) 2002-07-24 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-Z- [1- (4- (N - ((4-methyl-piperazin-1-yl) -methylcarbonyl) -N-methyl-amino) -anilino) -1-phenyl-methylene] -6-methoxycarbonyl- 2-indolinone monoethanesulfonate and its use as a medicament
CN101433519B (en) * 2008-12-19 2013-01-23 沈阳药科大学 Azithromycin eye drops and preparation method thereof
ES2384060B1 (en) * 2010-03-24 2013-09-23 Lipotec S.A. LIPID NANOPARTICLES CAPSULES.
EP2863884A1 (en) 2012-06-25 2015-04-29 Bayer HealthCare LLC Topical ophthalmological pharmaceutical composition containing pazopanib
KR20150083117A (en) 2012-11-08 2015-07-16 클리어사이드 바이오메디컬, 인코포레이드 Methods and devices for the treatment of ocular disease in human subjects
CN105555271A (en) 2013-09-20 2016-05-04 参天制药株式会社 Polyethylene glycol-containing composition
WO2016178064A1 (en) 2015-05-06 2016-11-10 Suven Life Sciences Limited Polymorph of nintedanib ethanesulphonate, processes and intermediates thereof
WO2016200688A1 (en) * 2015-06-06 2016-12-15 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
TWI700085B (en) * 2015-06-22 2020-08-01 新源生物科技股份有限公司 Use of ophthalmic formulations of tyrosine kinase inhibitors
CN108295072A (en) * 2015-12-09 2018-07-20 瑞阳(苏州)生物科技有限公司 Nintedanib prevents the purposes of eye disease
CN106902117A (en) 2015-12-23 2017-06-30 瑞阳(苏州)生物科技有限公司 A kind of medicine for preventing or treating CNV to be formed

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
JP2019534870A (en) 2019-12-05
CN107865821B (en) 2021-07-02
EP3515444A1 (en) 2019-07-31
CN107865821A (en) 2018-04-03
US10772885B2 (en) 2020-09-15
JP7018939B2 (en) 2022-02-14
US20190224194A1 (en) 2019-07-25
WO2018054077A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
EP3390634A4 (en) Compositions and methods for treatment of eye diseases
EP3464381A4 (en) Compounds and methods for the treatment of trop2 positive diseases
EP3177732A4 (en) Compositions and methods for the treatment of ophthalmic diseases and conditions
EP3347368A4 (en) Compounds and formulations for treating ophthalmic diseases
EP3448398A4 (en) Compositions and methods for treatment of skin disorders
EP3347469A4 (en) Methods and compositions for the treatment of glaucoma
EP3389725A4 (en) Compositions and methods for treatment of central nervous system diseases
EP3463315A4 (en) Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization
EP3096617A4 (en) Compositions and methods for treating ocular diseases
EP3515444A4 (en) Composition for treating ocular diseases and methods of usage and making
EP3390666A4 (en) Compositions and methods for treatment of kidney diseases
EP3596063A4 (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
EP3240612A4 (en) Methods of treating retinal diseases
EP3238736A4 (en) Peptide for treating ocular diseases and composition for treating ocular diseases comprising same
EP3538119A4 (en) Compositions and methods for treating skin diseases and maintaining healthy skin
EP3265096A4 (en) Ophthalmic compositions and methods of use therefor
EP3411080A4 (en) Compounds and methods of treating rna-mediated diseases
EP3352749A4 (en) Compounds and compositions for the treatment of ocular disorders
EP3086809A4 (en) Compositions and methods of treating ocular diseases
EP3554505A4 (en) Methods of treating ocular disorders
EP3429584A4 (en) Compositions and methods for the treatment of presbyopia
EP3484526A4 (en) Compositions and methods for treatment of cardiac diseases
EP3481958A4 (en) Methods and compositions for treatment of disorders and diseases involving rdh12
EP3713553A4 (en) Compositions and methods for treatment of eye diseases
EP3618868A4 (en) Methods and compositions for treating allergic ocular diseases

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190423

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20200504

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/02 20060101ALI20200427BHEP

Ipc: A61K 31/496 20060101AFI20200427BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20221013